Clinical and pathological characteristics of 1278 patients with CLL according to IT occurrence
| . | CLL (1214) . | % . | CLL and IT (64) . | % . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 68 (32-91) | — | 66 (48-80) | — | .08* |
| 60 or younger | 313 | 26 | 18 | 28 | — |
| Older than 60 | 901 | 74 | 46 | 72 | — |
| Sex | |||||
| M | 716 | 59 | 42 | 65 | .27 |
| F | 498 | 41 | 22 | 35 | — |
| RAI stage | |||||
| 0 | 439 | 36 | 19 | 30 | .14 |
| 1 | 371 | 31 | 23 | 36 | — |
| 2 | 220 | 18 | 16 | 25 | — |
| 3 | 82 | 7 | 5 | 8 | — |
| 4 | 102 | 8 | 1 | 1 | — |
| Baseline | |||||
| WBC, ×109/L | 31 (2.2-560) | 43.1 (6.2-450) | .019* | ||
| Hb, g/L | 131 (38-177) | 130 (53-162) | .32* | ||
| Plt, ×109/L | 191 (7-768) | 152 (3-528) | <.001* | ||
| Splenomegaly | |||||
| Yes | 397 | 33 | 21 | 33 | .58 |
| No | 817 | 67 | 43 | 67 | — |
| Positive DAT | 61 | 5 | 14 | 22 | <.001 |
| Elevated LDH | 339 | 28 | 15 | 26 | .31 |
| AHA | 37 | 3 | 10 | 16 | <.001 |
| IgVh status | |||||
| Mutated† | 93 | 54 | 5 | 18 | <.001 |
| Unmutated | 78 | 46 | 22 | 82 | — |
| Months to CLL treatment | 14.6 (0-120) | — | 15.4 (0-108) | — | .16* |
| Therapy for CLL | |||||
| No | 510 | 42 | 13 | 18 | .001 |
| Yes | 704 | 58 | 51 | 82 | — |
| First-line therapy | |||||
| Chl‡ | 506 | 72 | 44 | 86 | .09 |
| Fludarabine-based | 198 | 28 | 7 | 14 | — |
| Any fludarabine§ | 276 | 23 | 18 | 28 | .17 |
| . | CLL (1214) . | % . | CLL and IT (64) . | % . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 68 (32-91) | — | 66 (48-80) | — | .08* |
| 60 or younger | 313 | 26 | 18 | 28 | — |
| Older than 60 | 901 | 74 | 46 | 72 | — |
| Sex | |||||
| M | 716 | 59 | 42 | 65 | .27 |
| F | 498 | 41 | 22 | 35 | — |
| RAI stage | |||||
| 0 | 439 | 36 | 19 | 30 | .14 |
| 1 | 371 | 31 | 23 | 36 | — |
| 2 | 220 | 18 | 16 | 25 | — |
| 3 | 82 | 7 | 5 | 8 | — |
| 4 | 102 | 8 | 1 | 1 | — |
| Baseline | |||||
| WBC, ×109/L | 31 (2.2-560) | 43.1 (6.2-450) | .019* | ||
| Hb, g/L | 131 (38-177) | 130 (53-162) | .32* | ||
| Plt, ×109/L | 191 (7-768) | 152 (3-528) | <.001* | ||
| Splenomegaly | |||||
| Yes | 397 | 33 | 21 | 33 | .58 |
| No | 817 | 67 | 43 | 67 | — |
| Positive DAT | 61 | 5 | 14 | 22 | <.001 |
| Elevated LDH | 339 | 28 | 15 | 26 | .31 |
| AHA | 37 | 3 | 10 | 16 | <.001 |
| IgVh status | |||||
| Mutated† | 93 | 54 | 5 | 18 | <.001 |
| Unmutated | 78 | 46 | 22 | 82 | — |
| Months to CLL treatment | 14.6 (0-120) | — | 15.4 (0-108) | — | .16* |
| Therapy for CLL | |||||
| No | 510 | 42 | 13 | 18 | .001 |
| Yes | 704 | 58 | 51 | 82 | — |
| First-line therapy | |||||
| Chl‡ | 506 | 72 | 44 | 86 | .09 |
| Fludarabine-based | 198 | 28 | 7 | 14 | — |
| Any fludarabine§ | 276 | 23 | 18 | 28 | .17 |
DAT indicates direct antiglobulin test; AHA, autoimmune hemolytic anemia; Chl, chlorambucil; and —, not applicable.
Mann-Withney test was adopted to calculate P values of continuous variables.
Values not available in all patients (see text).
Includes 19 patients treated with COP or CHOP.
Refers to treatments delivered before IT diagnosis when applicable.